Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00207753
Other study ID # CDC-NCID-4283
Secondary ID
Status Completed
Phase N/A
First received September 13, 2005
Last updated November 16, 2005
Start date February 2005
Est. completion date March 2005

Study information

Verified date September 2005
Source Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

The aim of this study is to compare the efficacy and impact on growth of two drug treatments against intestinal worms in schoolchildren from a rural area of Guatemala. According to the World Bank, these intestinal worms are one of the top causes of childhood health problems in many areas of the developing world (The World Bank, 1993). Infected children are more likely to have inadequate nutrition due to the worm infections and are more likely to be shorter in height and weigh less than children who are not infected. After collecting height and weight information, we will split the children into two groups. One group will receive albendazole and the other group will receive combined albendazole/ivermectin. Both groups will be receiving albendazole, the current standard of care treatment. Ivermection is expected to improve efficacy and nutritional benefit as well as add increased scope of treatment for the worm Strongyloides, and ectoparasites such as scabies and head lice. Both treatment regimens and the combination have been used millions of times in the developing world and are safe to use. Co-administration of drugs would be a more efficient use of the opportunity to access schoolchildren and provide deworming treatment.


Description:

The aim of this study is to compare the efficacy and nutritional impact of two drug treatments against intestinal helminths from a rural area of Guatemala. The helminths that will be analyzed in this study are Ascaris lumbricoides, Trichuris trichiura, and hookworm. Because of the manifestations of these helminths infections, nutritional status can deteriorate in infected persons. According to the World Bank, these helminths are one of the top causes of childhood morbidity in many areas of the developing world (The World Bank, 1993).

This information will be gathered by collecting stool samples from schoolchildren, in order to determine the prevalence of infection in children living around Poptun, Guatemala. Height and weight measurements will also be taken, along with a visual exam of the skin for other parasitic skin infections. Children with an inadequate nutritional status are likely to be shorter in height and weigh less than children reared in an area with a low prevalence of helminths. After collecting this baseline information, we will split the children into two groups. One group will receive albendazole and the other group will receive albendazole/ivermectin. Both groups will be receiving is albendazole, the current standard of care treatment. Ivermectin is expected to improve efficacy and nutritional benefit as well as adding increased scope of treatment (Strongyloides, ectoparasites such as scabies and head lice). Both treatment regimens and the combination have been used millions of times in the developing world and are safe to use. Co-administration of drugs is thought to be a more efficient use of the opportunity to access schoolchildren and provide health improvements. Providing data to support expanded treatment options will provide public health officials with the data needed to make such decisions.


Recruitment information / eligibility

Status Completed
Enrollment 550
Est. completion date March 2005
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 5 Years to 12 Years
Eligibility Inclusion Criteria:

Children will be eligible to participate in the study if they are between 5 and 12 years of age, are students in schools selected for study, and if parental consent and child assent for participation has been obtained.

Exclusion Criteria:

those not fitting criteria above

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
albendazole vs. combined albendazole/ivermectin treatment


Locations

Country Name City State
Guatemala Various elementary schools Poptun Peten

Sponsors (2)

Lead Sponsor Collaborator
Centers for Disease Control and Prevention Universidad del Valle, Guatemala

Country where clinical trial is conducted

Guatemala, 

References & Publications (4)

Horton J, Witt C, Ottesen EA, Lazdins JK, Addiss DG, Awadzi K, Beach MJ, Belizario VY, Dunyo SK, Espinel M, Gyapong JO, Hossain M, Ismail MM, Jayakody RL, Lammie PJ, Makunde W, Richard-Lenoble D, Selve B, Shenoy RK, Simonsen PE, Wamae CN, Weerasooriya MV. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology. 2000;121 Suppl:S147-60. Review. — View Citation

Stephenson LS, Latham MC, Ottesen EA. Global malnutrition. Parasitology. 2000;121 Suppl:S5-22. Review. — View Citation

Stephenson LS, Latham MC, Ottesen EA. Malnutrition and parasitic helminth infections. Parasitology. 2000;121 Suppl:S23-38. Review. — View Citation

World Health Organization, 1992. Health of school children: treatment of intestinal helminths and schistosomiasis. Geneva: WHO.

Outcome

Type Measure Description Time frame Safety issue
Primary efficacy against geohelminths (stool egg count)
Primary height increase
Primary weight increase
Secondary ectoparasite examination
See also
  Status Clinical Trial Phase
Completed NCT03278431 - Triple Combinations Against Hookworm Infections in Lao Phase 4
Completed NCT01717950 - Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults Phase 1
Completed NCT02143518 - Safety and Immunogenicity Study of Na-GST-1 With or Without CpG Phase 1
Completed NCT02126462 - Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults Phase 1
Completed NCT01261130 - Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults Phase 1
Completed NCT01385189 - Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant Phase 1
Terminated NCT00473967 - Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults Phase 1
Completed NCT00603889 - Development of a Skin Test for the Na-ASP-2 Hookworm Antigen N/A
Completed NCT02839161 - Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children Phase 1
Completed NCT02476773 - Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults Phase 1
Recruiting NCT01940757 - Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae Phase 1
Completed NCT03373214 - Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults Phase 1
Completed NCT00939198 - Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil N/A
Active, not recruiting NCT02262403 - Hookworm Immune Regulation Project N/A
Completed NCT00120081 - Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection Phase 1
Recruiting NCT05914363 - Evaluating Impact of Improved Floors on Health N/A